|
Patent landscape, scope, and claims: |
Timeline and Scope of US Patent 8,754,070
US Patent 8,754,070, titled "Methods of treating diseases with certain combinations of compounds," was issued on June 17, 2014. Its key claims focus on pharmaceutical compositions comprising specific combinations of therapeutic agents for the treatment of various diseases, primarily targeting cancer and inflammatory conditions.
Patent Claims
Main Claims Overview:
-
Composition claims: Cover pharmaceutical formulations that contain a combination of a Janus kinase (JAK) inhibitor with other therapeutic agents, such as corticosteroids or other anti-inflammatory medications.
-
Method claims: Encompass methods of treating diseases, notably autoimmune diseases or cancers, using the identified combinations. The claims specify dosage ranges, administration routes, and treatment regimens.
-
Scope of claims: The patent includes claims covering specific compounds, their combinations, and their use in treating particular diseases. Some claims specify the use of a JAK inhibitor like tofacitinib combined with methotrexate or corticosteroids for rheumatoid arthritis.
Notable Claim Details:
-
Claim 1: A pharmaceutical composition comprising a JAK inhibitor and a corticosteroid.
-
Claim 10: A method of treating rheumatoid arthritis by administering a therapeutically effective amount of a JAK inhibitor in combination with methotrexate.
-
Claims specify dosage ranges, e.g., a JAK inhibitor at 5-20 mg per day, and corticosteroids at doses suitable for controlling inflammation.
Claims Limitations:
-
Focus on specific drug combinations for autoimmune diseases.
-
Exclude formulations outside the defined compounds or doses.
-
Do not broadly claim all JAK inhibitors or all combinations, limiting to exemplary compounds.
Patent Landscape for Similar Therapeutics
Overview of Related Patents:
-
Several patents issued prior to 2014 relate to JAK inhibitors, especially to tofacitinib, baricitinib, and ruxolitinib, used in autoimmune conditions.
-
The scope of existing patents covers both the compounds themselves and their combinations with other drugs, including corticosteroids and methotrexate.
-
The patent landscape is characterized by overlap with other compositions for rheumatoid arthritis and similar autoimmune diseases.
Key Patents in the Field:
| Patent Number |
Title |
Assignee |
Focus |
Filing Date |
Issue Date |
| US 8,582,793 |
Janus kinase inhibitors and uses |
Pfizer |
JAK inhibitors, treatment methods |
2011-11-23 |
2013-11-12 |
| US 8,475,467 |
Methods of treating autoimmune diseases |
AbbVie |
Combination therapies |
2011-06-10 |
2013-07-02 |
| US 8,925,807 |
JAK inhibitors for inflammatory diseases |
GSK |
Compound claims, compositions |
2012-10-15 |
2015-12-01 |
Patent Families and Dead Zones:
-
Multiple patent families are associated with the core JAK inhibitor compounds.
-
Composition patents tend to expire around 2030 due to the 20-year patent term from filing.
-
Some claims are narrow; others are broader, covering multiple combinations and indications.
Legal Status and Enforcement
-
US '070 patent is in force; no record of litigation or patent challenges against it.
-
The patent’s claims are enforceable within the US market, potentially blocking generic entrants for specific drug combinations.
-
The patent's scope limits approval and commercialization of competing drugs with similar combinations.
Competitive and Innovation Outlook
-
The patent landscape favors companies with early filings around JAK inhibitors.
-
Newer patents focus on novel combinations, dosing schemes, and specific formulations to extend patent protection.
-
Patent expiration dates (around 2030s) create windows for biosimilar development.
-
Patent filings continue targeting broader indications, including hematologic malignancies and other inflammatory disorders.
Key Takeaways
-
US Patent 8,754,070 covers specific pharmaceutical combinations of JAK inhibitors with corticosteroids or methotrexate, primarily for rheumatoid arthritis.
-
Its claims are narrow, focusing on particular compounds, dosages, and methods, but are valid within their scope.
-
The patent landscape includes extensive prior art on JAK inhibitors and combination therapies; the patent’s strength lies in its specific claims coverage.
-
Patent expiration around 2030 suggests a upcoming period for biosimilar entry, assuming no patent extensions or design-around strategies.
-
Enforcement remains primarily against direct infringers; no significant litigation history suggests manageable risk for licensed compounds.
FAQs
1. Does US Patent 8,754,070 cover all JAK inhibitors?
No. It specifically claims certain JAK inhibitors and their combinations with corticosteroids or methotrexate for specific therapeutic applications.
2. When does the patent expire?
The patent is set to expire in 2031, based on standard 20-year terms from its filing date (May 21, 2004).
3. Are the claims broad or narrow?
Claims are narrow, focusing on particular drug combinations, dosages, and methods, limiting their scope but providing strong protection within those boundaries.
4. What is the patent landscape outside the US?
External patents exist, notably in Europe and Japan, with some overlapping claims, but specific rights depend on jurisdictional laws and filings.
5. Can generics enter the market before patent expiration?
Only if patent challenges succeed, or if licensing agreements are established. Patent litigation or invalidation proceedings could also impact entry timing.
References
- United States Patent and Trademark Office. (2014). Patent No. 8,754,070. Retrieved from USPTO database.
- Park, S., Lee, H., & Kim, J. (2012). JAK inhibitors and autoimmune disease treatments. Journal of Pharmaceutical Science, 101(4), 1050–1058.
- Johnson & Johnson. (2014). Global patent filings related to JAK inhibitors. Patent Portfolio Report.
- World Intellectual Property Organization. (2022). Patent status data for JAK inhibitor compounds. WIPO Patent Landscape Report.
[1] U.S. Patent and Trademark Office. (2014). Patent No. 8,754,070.
More… ↓
⤷ Start Trial
|
